disease	mesh_id	drug	phase	start_date	completion_date	nct_id
Carcinoma, Non-Small-Cell Lung	D002289	afatinib	Phase 1	2009	2020	NCT03711422;NCT03827070;NCT02191891;NCT01288430;NCT01647711;NCT03054038;NCT01090011;NCT00993499;NCT04448379;NCT01999985;NCT02364609
Carcinoma, Non-Small-Cell Lung	D002289	afatinib	Phase 2	2007	2020	NCT02716311;NCT02098954;NCT02369484;NCT03810872;NCT02595840;NCT02795156;NCT03574402;NCT02747953;NCT02488694;NCT03157089;NCT04148898;NCT03623750;NCT02470065;NCT02597946;NCT04470076;NCT01932229;NCT01542437;NCT03727724;NCT04497584;NCT01415011;NCT02906163;NCT01003899;NCT02183883;NCT00730925;NCT00525148;NCT03399669;NCT00711594;NCT01156545;NCT00796549;NCT02450656;NCT01746251
Carcinoma, Non-Small-Cell Lung	D002289	afatinib	Phase 3	2008	2015	NCT02044380;NCT02438722;NCT01853826;NCT01523587;NCT01814553;NCT01121393;NCT00656136;NCT00949650;NCT01085136;NCT01953913
Carcinoma, Non-Small-Cell Lung	D002289	afatinib	Phase 4	2014	2020	NCT04413201;NCT02695290;NCT02208843;NCT04356118;NCT02514174
Urinary Bladder Neoplasms	D001749	afatinib	Phase 2	2013	2015	NCT02122172;NCT02465060
Urethral Neoplasms	D014523	afatinib	Phase 2	2013	2013	NCT02122172
Ureteral Neoplasms	D014516	afatinib	Phase 2	2013	2013	NCT02122172
Multiple Myeloma	D009101	afatinib	Phase 1	2020	2020	NCT03878524
Multiple Myeloma	D009101	afatinib	Phase 2	2015	2016	NCT02693535;NCT04439136;NCT02465060